FRONTEO Inc. (Headquarters: Minato-ku, Tokyo, President: Masahiro Morimoto, hereinafter FRONTEO) has a dissertation with the Department of Innovation Policy Research (Professor: Shingo Kano), Department of Medical Information and Life Sciences, Graduate School of Frontier Sciences, University of Tokyo. We have signed a license agreement for the use of the academic plan for educational and research institutions of the exploration AI system "Amanogawa".

Under this agreement, our Life Science AI CTO Hiroyoshi Toyoshiba gave a lecture at the intensive seminar "Knowing the field of research and development-what you need to know before career design" held by the graduate school on October 10. At that time, Professor Kano became interested in using "Amanogawa" in graduate school classes.

One of the challenges in searching for a treatise is that it is difficult to sufficiently detect the information discussed on the subject to be searched by keyword search alone.This is because one term may be used with multiple different meanings in the description of a treatise, or conversely, the same phenomenon or phenomenon may be described in various expressions including synonyms and abbreviations. .. In "Amanogawa", by using vectors for the search, articles related to the research theme are comprehensively detected, and those articles are displayed on the map based on the similarity of the concept, and the correlation etc. are visualized. , It will be possible to grasp the necessary papers from a bird's-eye view.Professor Kano highly evaluated this point, which led to the introduction of this product.

"Amanogawa" will be used in the lecture "Medical Innovation Bird's-eye View Exercise: A bird's-eye view of the research field and clarifying the position of one's interests in the world". FRONTEO hopes that "Amanogawa" will be utilized by students who will be responsible for the next generation of research and will contribute to new research and discoveries.

■Amanogawaabout URL: https://lifescience.fronteo.com/aidiscovery/amanogawa/

"Amanogawa (trademark / patent pending)" is a paper search AI system equipped with FRONTEO's original AI engine "Concept Encoder (registered trademark: concept encoder ®, reading: concept encoder)".When a researcher inputs a sentence such as a word or hypothesis of interest, "Concept Encoder" instantly detects the article related to the input content from the large number of articles published in PubMed *.

Since the search results are plotted in a map according to the similarity between the articles, you can check the relevance at a glance, and drag the article information detected on the map to narrow down the search, which is a visual that has never been seen before. You can search for articles.In addition, you can sort the search results in order of relevance and list their abstracts, greatly streamlining your article search.This makes it possible to discover events and new drug targets from a perspective that is difficult for humans to notice.

* PubMed: A database that allows you to search for articles in the field of biomedical science. Created by NCBI (National Center for Biotechnology Information) in NLM (National Library of Medicine).

■FRONTEOabout　URL: https://www.fronteo.com/

FRONTEO supports corporate business by extracting meaningful and important information from a huge amount of text data using the in-house developed AI engine "KIBIT®" and "concept encoder®" that specialize in natural language processing. It is a data analysis company. Since its establishment in August 2003, it has been expanding globally to Japan, the United States, South Korea, and Taiwan, focusing on legal tech businesses such as "e-discovery (electronic discovery)" and "digital forensic investigation" that support international litigation of companies. Has been deployed. From 8, based on the AI ​​technology cultivated in the legal tech business, we will expand the business field to the life science field and business intelligence field, and use AI to "turn text data into knowledge" to support drug discovery. We contribute to solving various corporate issues such as dementia diagnosis support, financial, personnel, and sales support. Listed on TSE Mothers on June 2014, 2007.The capital is 6 thousand yen (as of March 26, 2,568,651).